018| Volume 26, ISSUE 10, SUPPLEMENT , S9, October 2020

Sex-based Differences in Biomarkers, Quality of Life, and Reverse Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/valsartan


      Among patients with heart failure with reduced ejection fraction (HFrEF, left ventricular [LV] EF ≤ 40%), female sex is associated with differences compared to men.


      To determine sex-based differences in biomarkers, self-reported health status, and magnitude of longitudinal changes in measures of reverse cardiac remodeling among HFrEF patients treated with sacubitril/valsartan (S/V).


      This was a planned subgroup analysis of patients initiated on S/V in the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study.


      There were 226 (28.5%) women in the study. Though women had lower baseline N-terminal pro B-type natriuretic peptide (NT-proBNP), they had more rapid early reduction in the biomarker after initiation of S/V. Compared to men, women had lower average baseline Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 Total Symptom Score (67.6 vs 71.9; P =.003) but showed greater linear improvement (7.4 vs. 5.5 points; P <0.001) and faster pace of KCCQ change (-1.39 vs -1.09; P <0.001) over the course of the trial. Women had higher LVEF than men at baseline, however following S/V initiation, women reverse remodeled earlier than men, with more consistent change than in men. Reduction in NT-proBNP was associated with reverse cardiac remodeling in both women and men. Treatment with S/V was well tolerated in all.


      In women with HFrEF, treatment with S/V was well-tolerated, and associated with unique differences in NT-proBNP change, reverse cardiac remodeling and change in KCCQ-23 score compared to men (PROVE-HF; NCT02887183).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect